English | 简体中文 | 繁體中文 | 한국어
Share:
INVENTIVA to Participate in the "ROTH Battle of the NASH Thrones Investor Conference"


Inventiva to Participate in the "ROTH Battle of the NASH Thrones Investor Conference"

Daix (France), October 12, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that Pierre Broqua, Chief Scientific Officer and co-founder of Inventiva, will participate in the upcoming "ROTH Battle of the NASH Thrones Investor Conference" being held on October 17, 2018 at the Park Hyatt New York hotel, New York, USA.

Pierre Broqua will be speaking in the panel entitled "House of PPARs vs. House of THR-beta", one of the conference's four panel discussions covering topics currently at the forefront of drug development in NASH.

The event details are as follows:

Panel:                  "House of PPARs vs. House of THR-beta"
Date:                    Wednesday, October 17, 2018
Time:                    12:00 pm - 1:00 pm (Eastern Time)
Location:             Park Hyatt New York hotel, 153 West 57th St., New York, NY 10019, USA

About Inventiva: www.inventivapharma.com

Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva's research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Contacts

Inventiva
Frédéric Cren
Chairman & CEO
[email protected]
+33 3 80 44 75 00
Brunswick
Julien Trosdorf / Yannick Tetzlaff
Media relations
[email protected]
+33 1 53 96 83 83
LifeSci Advisors
Monique Kosse
Investor relations
[email protected]
+1 212 915 3820



This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: INVENTIVA via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
INGREDION INCORPORATED DECLARES QUARTERLY DIVIDEND OF $0.625 PER SHARE  
Dec 14, 2018 23:59 ET
Pöyry PLC: ÅF has published an update on its tender offer of Pöyry  
Dec 14, 2018 21:00 ET
BinckBank responds to recent press coverage  
Dec 14, 2018 20:09 ET
Pöyry PLC: Notice of change in ownership in compliance with Chapter 9, Section 10 of the Securities Market Act  
Dec 14, 2018 18:10 ET
Outcome of EU-wide Transparency Exercise  
Dec 14, 2018 18:04 ET
INGREDION INCORPORATED DECLARES QUARTERLY DIVIDEND OF $0.625 PER SHARE  
Dec 14, 2018 16:57 ET
INGREDION INVESTS $140 MILLION TO ACCELERATE GROWTH IN PLANT-BASED PROTEINS  
Dec 13, 2018 22:29 ET
CLX Communications AB (publ): CLX Communications appoints new CFO  
Dec 12, 2018 15:59 ET
Lubrizol Announces Strategic Alliance with Vidalia Denim for Sustainably-Produced Denim Featuring X4zol(TM)-J Stretch Fibers:  
Dec 11, 2018 06:59 ET
Eastman Board Increases Dividend for Ninth Consecutive Year  
Dec 7, 2018 05:29 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: